Edition:
United Kingdom

Michael Erman

U.S and European regulators reviewing safety of heartburn drugs like Zantac

13 Sep 2019

U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine.

Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion

26 Aug 2019

Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.

Novartis says it knew of Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation.

Novartis says knew about Zolgensma data problems before U.S. approval

07 Aug 2019

NEW YORK, Aug 7 Drugmaker Novartis on Wednesday acknowledged that there were discrepancies with data it had submitted to regulators for approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed its internal investigation.

U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulated

07 Aug 2019

NEW YORK The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis' more than $2 million gene therapy Zolgensma was manipulated, but the agency believes the treatment should remain on the market.

Trump firms up plan to import medicines; pharma companies resist

01 Aug 2019

The Trump administration took a step Wednesday toward allowing importation of medicines from Canada, an action the president has advocated as a way to bring cheaper prescription drugs to Americans, but the pharmaceutical industry was quick to resist the move.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

29 Jul 2019

Pfizer Inc has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar. | Video

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

25 Jul 2019

NEW YORK Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

World News

Iran says it will destroy any aggressor

Iran will pursue any aggressor, even if it carries out a limited attack, and seek to destroy it, the head of the elite Revolutionary Guards said on Saturday, after attacks on Saudi oil sites which Riyadh and U.S officials blamed on Tehran.